Pan HER family receptor inhibitors, i.e., second-generation EGFR TKIs, show inhibitory effects on NSCLC expressing HER2 with exon 20 insertions [114]; however, effective drugs for HER2 InsYVMA have not yet been developed. Here, EGFR is linked to non-small cell lung carcinoma.